Breaking News
Get 40% Off 0
🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks. Unlock full list
Close

Solasia Pharma KK (4597)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
27.0 +1.0    +3.85%
07:00:29 - Closed. Currency in JPY ( Disclaimer )
  • Volume: 6,030,400
  • Bid/Ask: 27.0 / 28.0
  • Day's Range: 26.0 - 29.0
Type:  Equity
Market:  Japan
ISIN:  JP3436500007 
Solasia Pharma 27.0 +1.0 +3.85%

4597 Balance Sheet

 
Assess the latest Solasia Pharma KK balance sheet. Review the company's financial position, assess their current assets, liabilities and shareholder equity across the most recent periods (either quarterly or annually).

Even more advanced 4597 Annual Report data, financial summaries and charts are available for Solasia Pharma KK investors with their own InvestingPro account.
AnnualQuarterly
Advanced Balance Sheet
Period Ending: 2023
31/12
2023
30/09
2023
30/06
2023
31/03
Total Current Assets 976 897 - 1353
Cash and Short Term Investments 728 520 453 1016
Cash - - - -
Cash & Equivalents 728 520 - 1016
Short Term Investments - - - -
Total Receivables, Net - 206 - 240
Accounts Receivables - Trade, Net 67 206 549 240
Total Inventory - 120 117 55
Prepaid Expenses 57 - - -
Other Current Assets, Total 2 51 52 42
Total Assets 2229 2278 - 2989
Property/Plant/Equipment, Total - Net - 92 - 116
Property/Plant/Equipment, Total - Gross - - - -
Accumulated Depreciation, Total - - - -
Goodwill, Net - - - -
Intangibles, Net 1117 1230 1343 1456
Long Term Investments 52 58 - 61
Note Receivable - Long Term - - - -
Other Long Term Assets, Total 49 1 3 3
Other Assets, Total 57 -35 -380 -143
Total Current Liabilities - 287 351 455
Accounts Payable - 212 273 374
Payable/Accrued - - - -
Accrued Expenses - - - -
Notes Payable/Short Term Debt - - - -
Current Port. of LT Debt/Capital Leases - 33 34 38
Other Current liabilities, Total - 42 44 43
Total Liabilities 354 365 445 565
Total Long Term Debt 27 36 44 52
Long Term Debt - - - -
Capital Lease Obligations 27 36 44 52
Deferred Income Tax 22 30 - 45
Minority Interest - - - -
Other Liabilities, Total 12 12 12 13
Total Equity - 1913 2233 2424
Redeemable Preferred Stock, Total - - - -
Preferred Stock - Non Redeemable, Net - - - -
Common Stock, Total 1596 1439 1436 1436
Additional Paid-In Capital 1657 1504 - 1500
Retained Earnings (Accumulated Deficit) - -992 - -464
Treasury Stock - Common -69 -70 -70 -70
ESOP Debt Guarantee - - - -
Unrealized Gain (Loss) - - - -
Other Equity, Total 27 32 27 22
Total Liabilities & Shareholders' Equity 2229 2278 2678 2989
Total Common Shares Outstanding 173.94 168.31 167.99 167.97
Total Preferred Shares Outstanding - - - -
* In Millions of JPY (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the balance sheet, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

4597 Price Commentary

Write your thoughts about Solasia Pharma KK
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email